Literature DB >> 2751284

Pharmacokinetic comparison of 5 g of azlocillin every 8 h and 4 g every 6 h in healthy volunteers.

R D Lander1, R P Henderson, D R Pyszczynski.   

Abstract

To compare the multiple-dose pharmacokinetics of two dosage regimens of azlocillin, we studied 12 healthy volunteers via a randomized, crossover design with a 2-week washout phase between regimens. Serum and urine samples were collected for 8 h following the fifth dose of a regimen of 4 g every 6 h and the fourth dose of a regimen of 5 g every 8 h. Data for concentrations in serum were fitted to a two-compartment open model by nonlinear regression. Statistically significant differences (P less than 0.05) were observed in the following parameters (mean +/- standard deviation) for the 4- and 5-g regimens, respectively: area under the serum concentration-time curve during the dosing interval, 592 +/- 140 versus 772 +/- 151 micrograms.h/ml; terminal elimination rate constant, 0.5364 +/- 0.0912 versus 0.4758 +/- 0.0486 h-1; renal clearance, 87.6 +/- 16.1 versus 76.1 +/- 13.5 ml/min; maximum drug concentration in serum, 381 +/- 89 versus 473 +/- 90 micrograms/ml; and minimum drug concentration in serum, 19 +/- 10 versus 8 +/- 4 micrograms/ml. No significant differences were seen in the following parameters: V1, V beta, k10, k12, k21, total systemic clearance, and nonrenal clearance. These data support the presence of saturable renal elimination of azlocillin, as well as the feasibility of an 8-h dosing interval.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751284      PMCID: PMC172519          DOI: 10.1128/AAC.33.5.710

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Comparative pharmacokinetics of azlocillin and piperacillin in normal adults.

Authors:  P A Colaizzi; R E Polk; W J Poynor; A C Raffalovich; E A Cefali; L A Beightol
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

2.  High-pressure liquid chromatographic quantitation of azlocillin.

Authors:  A Weber; K E Opheim; K Wong; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 3.  Review of the pharmacokinetics and dose dependency of azlocillin in normal subjects and patients with renal insufficiency.

Authors:  T Bergan
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

4.  Elimination of azlocillin in patients with biliary t-tube drainage.

Authors:  U Gundert-Remy; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin.

Authors:  L Coppens; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

Review 6.  [Clinical pharmacokinetics of azlocillin].

Authors:  E Singlas; C Haegel
Journal:  Presse Med       Date:  1984-03-29       Impact factor: 1.228

7.  International clinical experience with azlocillin.

Authors:  P Schacht; G Arcieri; H Bruck; E Griffith; R Hullman; D Tettenborn
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  The novel therapeutic implications of azlocillin's dose-dependent pharmacokinetics: contributing physiologic mechanisms and a prospective, cross-over designed trial.

Authors:  A Whelton; R L Stout; P S Spilman; F A Delgado; A J Watson
Journal:  J Clin Pharmacol       Date:  1987-07       Impact factor: 3.126

9.  Pharmacokinetics of azlocillin in healthy subjects.

Authors:  A Leroy; G Humbert; J P Fillastre
Journal:  Scand J Infect Dis Suppl       Date:  1981

10.  Pharmacokinetics of azlocillin in persons with normal and impaired renal functions.

Authors:  P Fiegel; K Becker
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.